Johnson Financial Group LLC Sells 1,083 Shares of Gilead Sciences, Inc. $GILD

Johnson Financial Group LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 33.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,150 shares of the biopharmaceutical company’s stock after selling 1,083 shares during the quarter. Johnson Financial Group LLC’s holdings in Gilead Sciences were worth $238,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of GILD. Brighton Jones LLC raised its holdings in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new position in Gilead Sciences during the 4th quarter worth about $215,000. Massachusetts Financial Services Co. MA increased its position in Gilead Sciences by 24.2% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 94,286 shares of the biopharmaceutical company’s stock valued at $10,565,000 after purchasing an additional 18,368 shares during the period. Diversify Advisory Services LLC raised its holdings in shares of Gilead Sciences by 44.1% in the 1st quarter. Diversify Advisory Services LLC now owns 3,622 shares of the biopharmaceutical company’s stock valued at $377,000 after purchasing an additional 1,109 shares in the last quarter. Finally, Private Advisor Group LLC lifted its position in shares of Gilead Sciences by 10.4% in the 1st quarter. Private Advisor Group LLC now owns 38,275 shares of the biopharmaceutical company’s stock worth $4,289,000 after purchasing an additional 3,593 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 0.1%

Shares of Gilead Sciences stock opened at $125.02 on Monday. The firm’s 50 day simple moving average is $117.44 and its two-hundred day simple moving average is $112.88. The firm has a market capitalization of $155.11 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a 12-month low of $86.08 and a 12-month high of $127.68. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the previous year, the business earned $2.02 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. The Goldman Sachs Group increased their target price on Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Truist Financial reissued a “buy” rating and set a $145.00 price target (up from $127.00) on shares of Gilead Sciences in a research report on Monday, November 3rd. Rothschild & Co Redburn lifted their price objective on shares of Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. Wolfe Research boosted their price objective on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research note on Thursday, October 23rd. Finally, Wall Street Zen upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $129.13.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the sale, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at $18,545,054.40. This represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Deborah H. Telman sold 53,646 shares of Gilead Sciences stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the transaction, the executive vice president owned 43,676 shares of the company’s stock, valued at approximately $5,365,596.60. This represents a 55.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 94,646 shares of company stock valued at $11,311,286. Insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.